• Follow us
  • Holding BUMN Farmasi
  • For Healthcare Professional
  • Researcher
  • EN
    Flag IndonesiaID
    Flag EnglishEN
biofarma-logo-bumn biofarma-logo biofarma-logo-131 biofarma-logo-hashtag-only-case
  • Home
  • Who We Are

    About Us
    • Our Focus
    • Our Strategy
    • Our Distribution
    • Our Operations
    • Your Career
    Our Leadership
    • Corporate Executive Team
    • Management Team
    Our Achievement
    • Awards
    • Certification
    Sustainability
    • Our People
    • Access to Vaccine
    • Corporate Social Responsibility
    • Good Corporate Governance
    • Biodiversity
  • Product & Service

    Our Product
    • Combination Vaccine
    • Viral Vaccine
    • Bacterial Vaccine
    • Diagnostic Vaccine
    • Sera
    Our Health Service
    • Service of Industrial Micro Biology
    • Clinical Laboratory Service
    • Vaccination Service
    • Clinic & Pharmacy

    Visit our website

  • Media

    For Media
    • Latest News
    • Current Event
    Vaccine Fact
    Media Release
    FAQ
  • I Want to
search

Bio Farma Has Secured the Availability of the Covid-19 Vaccine for Indonesia

Thursday, 15 July 2021

(Bandung 14/7) Bio Farma received a working visit from the Deputy Chair of the House of Representatives People's Welfare Sector Muhaimin Iskandar (14/7). During this working visit, he was accompanied by several members of the DPR-RI, and the Indonesian Minister of Manpower and Transmigration Ida Fauziah was also present. This Working Visit was welcomed by the President Director, Bio Farma, Honesti Basyir, and the Director of Operations at Bio Farma, Rahman Roestan.

In his speech, Muhaimin Iskandar said Bio Farma has a long history, and Bio Farma is the hope of all of us, in overcoming difficulties, especially during the pandemic through biotechnology.

“I and the leaders of the DPR will always support Bio Farma. We will continue to fulfill Bio Farma's need to become the "Sword of the Nation in the fight against the Covid19 virus. We encourage Bio Farma to form a consortium with similar companies at home and abroad, in order to be better able to accelerate the production of more vaccines," said Muhaimin.

He also added that during this pandemic, collaboration is needed, individually or jointly through synergy between the DPR and SOEs, especially Bio Farma and can be even more advanced in the future.

Meanwhile, Ida Fauziah said that the procurement of the Mutual Cooperation Vaccination (VGR) program for employment is very important, especially for those who work in essential and critical sectors. Currently, the labor and worker groups are a vulnerable group, especially in public services, especially in the critical and essential sectors. 

"To be able to escape from this pandemic period, we are faced with a choice, namely through strict Health Protocols, and accelerating the provision of vaccinations. We also give appreciation and support for the maximum contribution that has been made by Bio Farma in ensuring the availability of vaccine allocations and additional vaccine allocations for labor-intensive industries,” said Ida Fauziah.

During this visit, Bio Farma also received an award from the Indonesian Ministry of Manpower and Transmigration as a company that helps build herd immunity through the Covid-19 Vaccination Program for workers and their families. 

In an explanation from Honesti Basyir, he said that until now, Bio Farma has continued to make efforts to bring in the Covid-19 vaccine from various sources. To obtain this COVID-19 vaccine, Indonesia uses a bilateral approach as well as a multilateral approach.

This bilateral approach has been carried out by Bio Farma and has arrived at Bio Farma as many as 115.5 million bulk from Sinovac, while with Sinopharm producer for the purpose of Vaksinasi Gotong Royong (VGR), at least 3.7 million doses have arrived. As for the multilateral route, through the Covax Facility collaboration, at least 16.2 million have been received, bringing the total number of vaccines received by Indonesia to 137.6 million doses.

“The first vaccine was delivered in December 2020 in finished form, which is 3 million doses. And now, Bio Farma is able to produce its own vaccine from Sinovac. For the contract with Bio Farma, SInovac has agreed to send 140 million doses, and based on the direction from the Ministry of Health, there will be an option to add another 120 million doses,' Honesti said.

Bio Farma, which is also the Holding Holding Company for Pharmaceutical SOEs, is committed to handling Covid-19 through the provision of Covid-19 vaccines as well as medical therapy for Covid-19. In addition to vaccines and medical therapy, Bio Farma and the biotechnology startup Nusantics launched the latest innovation in the form of a diagnostic called Bio Saliva, which is a test tool to detect Covid-19 using the gargling method. This method is much more convenient for detecting the Covid-19 virus in the body of patients with or without symptoms. (ed)

  • Share to:
Download

Latest News

PIALA BMGF
Thursday, 19 May 2022
Bio Farma Receives Appreciation from the Bill and Melinda Gates Foundation
BIO FARMA MDI
Wednesday, 11 May 2022
Building Bio-Health Fund, Bio Farma Together with MDI Invest to Targeting Opportunities in Health Sector Startups
Ilustrasi produksi BF
Thursday, 24 February 2022
Bio Farma to Receive mRNA Vaccine Transfer Technology
View more

Head Office
Jl. Pasteur No. 28, Bandung 40161,
Jawa Barat Indonesia
No. Telp
+62 22-2033755
Fax
+62 22 - 2041306
Bio Care
1500810
Email
mail@biofarma.co.id
website
www.biofarma.co.id
Digital Healthcare Office Jakarta Lt. 26
Equity Tower Sudirman Central Business District (SCBD) Lot 9
Jl. Jend. Sudirman Kav. 52-53
Jakarta Selatan 12190, Indonesia
Information
  • Good Corporate Governance
  • Our Procurement
  • FAQ
  • Vaccine Production
  • Your Career
 
  • Contact Us
  • E-PPID
  • Announcement
  • I Want to
  • Media Release
Our Partner

Quick Links
  • Portal BUMN-Bio
  • Kemenkes RI
Copyright © 2022. All Rights Reserved by Bio Farma
Holding BUMN Farmasi
For Healthcare Professional
Researcher

Change Language

EN
  • Home
  • Who We Are
    • About Us
      • About Us
      • Our Focus
      • Our Strategy
      • Our Distribution
      • Our Operations
      • Your Career
    • Our Leadership
      • Corporate Executive Team
      • Management Team
    • Our Achievement
      • Awards
      • Certification
    • Sustainability
      • Our People
      • Access to Vaccine
      • Corporate Social Responsibility
      • Good Corporate Governance
      • Biodiversity
  • Product & Service
    • Our Product
      • Our Product
      • Combination Vaccine
      • Viral Vaccine
      • Bacterial Vaccine
      • Diagnostic Vaccine
      • Sera
    • Our Health Service
      • Our Health Service
      • Service of Industrial Micro Biology
      • Clinical Laboratory Service
      • Vaccination Service
      • Clinic & Pharmacy
  • Media
    • For Media
      • For Media
      • Latest News
      • Current Event
    • Vaccine Fact
    • Media Release
    • FAQ
  • I Want to
  • Follow us
Change Language
  • Flag IndonesiaID
  • Flag EnglishEN
BIO CARE 1500810 icon-phone
Youtube icon-youtube
Corporate Reporting icon-statistics